Eugene

[email protected]

LATEST

White House Meets with Pharma Executives to Advance Coronavirus Treatments and Vaccines
By

By
President Donald Trump and executives discuss progress and needs in advancing vaccines and treatments against coronavirus; also, news from Takeda and Vir Biotechnology. White House Meets with Pharma Executives to…

AstraZeneca Completes Sale of Five Hypertension Drugs for $350 M
By

By
AstraZeneca has completed an agreement with Atnahs Pharma, a UK-based pharmaceutical company, to divest its global commercial rights for five established hypertension medicines for $350 million. The medicines include Inderal (propranolol), a…

Takeda Acquires PVP Biologics for Up To $330 Million
By

By
Takeda Pharmaceutical has acquired PvP Biologics, a San Diego, California-based pharmaceutical company developing treatments for celiac disease, in a deal worth up to $330 million. The acquisition follows the conclusion…

Takeda Divesting Select OTC and Rx Drugs in Three Deals Totaling $1.7 Bn
By

By
As part of a strategy to divest non-core assets to reduce debt following its $62-billion acquisition of Shire in 2019, Takeda has completed the sale of select over-the-counter (OTC) and…

Biogen, Sangamo in $2.72-Bn Deal for Gene-Regulation Therapies in Neurology
By

By
Biogen and Sangamo Therapeutics, a genomic medicine company, have formed a global licensing collaboration agreement for gene-regulation therapies in neurology in a deal worth up to $2.72 billion ($350 million…

Gilead To Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion
By

By
Gilead Sciences has agreed to acquire Forty Seven, Inc. a clinical-stage immuno-oncology company, for $95.50 per share in cash or $4.9 billion. Forty Seven’s lead investigational lead product candidate is magrolimab,…

AbbVie Moves Closer to Finalizing Pending $63-Bn Acquisition of Allergan
By

By
AbbVie has moved closer to finalizing its pending $63-billion acquisition of Allergan following approval by the European Commission of the divestiture of Allergan’s brazikumab, an investigational drug to treat autoimmune…

Global Pharma Briefs: News from Asia, Europe and the US
By

By
A roundup of developments from Malaysia (Biocon), Saudi Arabia (Grifols), UK (AstraZeneca), and the US (Merck & Co., Taro Pharmaceuticals). Malaysia Biocon Receives FDA Form 483 for Insulin Mfg Plant…

GSK To Sell 15 Consumer Healthcare Products to Stada
By

By
GlaxoSmithKline (GSK) has agreed to sell to Stada, a Bad Vilbel, Germany-based company, a portfolio of 15 local and regional consumer healthcare brands in countries predominantly in Europe for an…

GSK, Immatics Partner to Develop Adoptive Cell Therapies in $600-M-Plus Pact
By

By
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company for T-cell redirecting cancer immunotherapies, has entered into a strategic collaboration agreement with GlaxoSmithKline (GSK) to develop novel adoptive cell therapies targeting multiple…